Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

• Novo Nordisk faces intensifying competition in the GLP-1 market, with Eli Lilly continuing to pull ahead in the U.S. market and Roche reporting mid-stage data for its experimental enicepatide, which showed 15.5% average weight loss. This broadening competition threatens Novo's market share and pricing power, as rivals offer comparable or superior efficacy, potentially eroding the company's dominant position in obesity and diabetes care.
• The company recently cut its dividend, reducing the payout from $1.2751 per share to $0.5786 per share, which was paid on August 25, 2026. This negative change in dividend policy may disappoint income-focused investors and could signal that management is prioritizing capital preservation or other strategic investments over shareholder returns, potentially impacting the stock's appeal as a defensive holding.
• Analyst sentiment remains cautious, with a consensus rating of "Hold" and a recent downgrade from Deutsche Bank Aktiengesellschaft from "hold" to "sell" on August 27, 2026. Additionally, Zacks Research and Weiss Ratings have only recently upgraded their ratings to "hold," indicating that many analysts still see significant risks or lack of near-term catalysts for a strong price appreciation, despite the current low valuation.
• Novo Nordisk has yet to demonstrate a convincing "second act" beyond its flagship weight-loss franchise, as investors remain concerned about the company's ability to sustain growth in a highly competitive landscape. The reliance on a limited number of blockbuster drugs, such as Ozempic and Wegovy, creates concentration risk, and any regulatory or competitive setbacks in these areas could have a disproportionate impact on the company's overall financial performance.
• The stock has experienced significant volatility and a sharp decline from its 52-week high, with a recent gap down of 2.19% on September 21, 2026, and a broader trend of selling pressure. This downward momentum, combined with a beta of 0.74, suggests that while the stock is less volatile than the market, it is still susceptible to sector-wide sell-offs and negative sentiment, which could lead to further price declines if market conditions deteriorate.